Centessa Pharmaceuticals plc (CNTA)
Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861.
In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas.
Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | May 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Dr. Saurabh Saha M.D., Ph.D. |
Contact Details
Address: 3rd Floor, 1 Ashley Road Altrincham, Cheshire, X0 WA14 2DT United Kingdom | |
| Phone | 44 7391 789784 |
| Website | centessa.com |
Stock Details
| Ticker Symbol | CNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001847903 |
| CUSIP Number | 152309100 |
| ISIN Number | US1523091007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Gregory M. Weinhoff M.B.A., M.D., MBA | Principal Accounting Officer and Chief Financial Officer |
| Dr. Antoine Yver M.D., M.Sc., MSc | Executive Vice President and Chairman of Development |
| Dr. Thomas S. Templeman Ph.D. | Chief Technology Officer |
| Dr. David M. Chao Ph.D. | Chief Administrative Officer |
| Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Karen M. Anderson | Chief People Officer |
| Tia L. Bush | Chief Quality Officer |
| Dr. David John Grainger Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 25, 2023 | 8-K | Current Report |
| Sep 20, 2023 | 144 | Filing |
| Sep 1, 2023 | 144 | Filing |
| Aug 24, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | 8-K | Current Report |
| Aug 1, 2023 | 144 | Filing |
| Jul 10, 2023 | 8-K | Current Report |